Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of GZR18 injection in Chinese adults with type 2 diabetes mellitus inadequately controlled on oral therapy
CTR20244764Phase 3Completed
- Sponsor
- Gannex Pharma Co., Ltd.
- Start
- Feb 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bofanglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Gannex Pharma Co., Ltd. Started Feb 2025; status: completed.
02
Drugs
bofanglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20244764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244764.